Showing Funds Performance since Sep 07, 2020

| Duration | Fund Return(%) | Category Average(%) | Category Best(%) |
|---|---|---|---|
| 1M | 4.16 | 0.56 | 4.28 |
| 6M | 17.99 | 2.68 | 26.58 |
| 1Y | 7.28 | 5.04 | 16.25 |
| 3Y | 19.42 | 14.81 | 92.97 |
Tata India Pharma & HealthCare Fund Growth managed by Tata Mutual Fund,is a Healthcare & Pharmascheme with Assets Under Management of ₹1,455 Crore. The fund benchmarks its performance against the BSE Healthcare Total Return while maintaining an expense ratio of 2.25. Under the expert guidance of Rajat Srivastava ,the fund implements a disciplined investment approach aligned with its mandate. The scheme requires a minimum investment of ₹500 for SIP and ₹1,000 for lump sum investments, making it accessible to diverse investor profiles.
Mr. Rajat Srivastava has done BBA (Banking & Insurance), PGDM - IMT Ghaziabad. Prior to joining Tata Mutual Fund, he has worked with Incred Asset Management, Kotak Investment Banking, Emkay Global, Evalueserve and Motilal Oswal Financial Services.
| Fund Name | Ratings | AUM | Expense Ratio |
|---|---|---|---|
| Nippon India Pharma Fund Growth | 4 | 9,044 CR | 1.86 |
| Tata India Pharma & HealthCare Fund Growth | 2 | 1,455 CR | 2.25 |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund Growth | 5 | 6,624 CR | 2.1 |
| UTI Healthcare Fund Growth | 3 | 1,307 CR | 2.26 |
| Fund Name | 1Y | 3Y |
|---|---|---|
| This FundNippon India Pharma Fund Growth | 6.3345 | 66.8428 |
| This FundTata India Pharma & HealthCare Fund Growth | 7.2845 | 70.3269 |
| This FundICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund Growth | 5.4256 | 86.9175 |
| This FundUTI Healthcare Fund Growth | 11.4583 | 87.3698 |